The HTT gene sits on chromosome 4 and encodes huntingtin, a large protein involved in transporting cellular cargo, maintaining mitochondria, and regulating gene activity. When a short repeating stretch of DNA within this gene expands beyond a critical threshold, the result is Huntington’s disease, a progressive neurodegenerative condition that destroys specific brain cells over decades. What makes the HTT story unusually rich is that the normal protein is not just background machinery; it is essential for survival from the earliest stages of embryonic development, and the mutation that causes disease does not simply break the protein but warps it into something actively toxic.
What the Normal Huntingtin Protein Does
Huntingtin is expressed in virtually every cell in the body, but it is especially abundant in the brain. Its best-understood job is acting as a scaffolding protein that organizes the transport of various cargo along the internal highway system of a cell. This includes vesicles carrying brain-derived neurotrophic factor (BDNF), a molecule crucial for keeping neurons alive, as well as early endosomes, autophagosomes, lysosomes, and mitochondria.1PubMed. The Huntingtin Transport Complex Think of huntingtin as a logistics coordinator: it does not carry the packages itself but makes sure the right molecular motors attach to the right cargo and move it in the right direction.
The protein is also critical for mitochondrial health. Experiments in mouse embryonic stem cells show that removing huntingtin entirely leads to defective mitochondrial structure and energy production, and embryos that lack the protein die very early in development.2PubMed Central. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells That early lethality tells us something important: huntingtin is not a luxury protein. Cells cannot function without it, which is one reason that therapeutic strategies for Huntington’s disease try to reduce the mutant version of the protein without completely eliminating the normal one.
Beyond transport and mitochondria, huntingtin plays a role in autophagy, the cell’s internal recycling program that clears out damaged components. Normal huntingtin appears to help regulate several steps in the autophagy process, from forming the initial membrane sac that engulfs waste to fusing that sac with the digestive compartment (the lysosome) that breaks it down.3PubMed. Autophagy in Huntington disease and huntingtin in autophagy This dual identity, where the normal protein actively supports autophagy and the mutant protein disrupts it, makes the disease doubly damaging.
The CAG Repeat and How It Causes Disease
Near the beginning of the HTT gene is a stretch where the DNA letters C-A-G repeat in a row. In most people, this stretch contains somewhere between about 10 and 35 repeats. At 36 repeats and above, the gene enters a gray zone: some individuals with 36 to 41 repeats develop Huntington’s disease within a normal lifespan, but others do not. Once the count reaches 42 or more, the mutation is fully penetrant, meaning virtually everyone who carries it will eventually show symptoms.4PubMed Central. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size The longer the repeat, the earlier symptoms tend to appear. A large international study of nearly 3,000 patients developed a model estimating the probability of symptom onset at different ages for each CAG repeat length between 36 and 56.5PubMed. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length
Huntington’s disease follows an autosomal dominant inheritance pattern: you only need one mutant copy to be affected. Each child of a carrier has a 50 percent chance of inheriting the expanded allele. But the repeat does not always pass on at the same length. During sperm production, expanded CAG repeats are especially prone to growing even longer. One study found a mutation frequency of roughly 0.7 for disease-range alleles during meiosis, meaning that in about 70 percent of transmissions the repeat changed length, and sperm production carried a greater risk of expansion than egg production.6Human Molecular Genetics. Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene This is why juvenile-onset Huntington’s disease, which accounts for roughly 5 percent of cases and involves onset before age 21, most often traces back to an affected father: the repeat expanded further during paternal transmission, pushing onset earlier.7PubMed Central. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease
This phenomenon, where successive generations get sicker younger because the repeat keeps growing, is called anticipation. It is not just a statistical curiosity. It means that a family’s experience of Huntington’s can shift dramatically across generations, with a grandparent who developed tremors in their sixties and a grandchild who develops rigidity and seizures as a teenager.
What Goes Wrong Inside the Cell
The extra CAG repeats translate into an abnormally long stretch of the amino acid glutamine near the front of the huntingtin protein. This “polyglutamine” tract makes the protein prone to misfolding, and the misfolded protein gets chopped into fragments by cellular enzymes. Those fragments are especially dangerous. Small pieces of mutant huntingtin accumulate both in the cytoplasm (around the nucleus) and inside the nucleus itself, forming clumps called inclusions.8PubMed. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions Work in a mouse model showed that fragments as small as the protein encoded by exon 1 alone can build up in neuronal nuclei before behavioral symptoms even appear.9Journal of Biological Chemistry. Proteolytic Cleavage of Huntingtin Generates Smaller Than Exon 1 Fragments That Accumulate in the Nucleus of the HdhQ150 Knock-in Mouse Model of Huntington’s Disease
Once inside the nucleus, mutant huntingtin interferes with gene expression. It directly inhibits key components of the transcription machinery, including the activator protein Sp1 and core transcription factors, in a manner that depends on the length of the polyglutamine tract.10PubMed. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets Mutant huntingtin also sequesters the transcription factor NF-Y, dragging it into protein aggregates and away from the genes it normally activates, leading to reduced expression of protective heat-shock proteins.11PubMed Central. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor Additional research suggests the mutant protein can bind directly to DNA and change its shape, broadly disrupting the binding of many transcription factors at once.12PubMed Central. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner
The damage extends to mitochondria and the cell’s recycling system. Multiple lines of evidence point to impaired mitochondrial energy production, disrupted mitochondrial trafficking, oxidative stress, and problems with calcium handling inside mitochondria as contributors to Huntington’s disease.13PubMed Central. Mitochondria in Huntington’s disease: implications in pathogenesis and mitochondrial-targeted therapeutic strategies Meanwhile, the autophagy system that should be clearing misfolded protein becomes dysfunctional, creating a vicious cycle in which toxic fragments accumulate faster than the cell can remove them.14PubMed Central. The many faces of autophagy dysfunction in Huntington’s disease: from mechanism to therapy
Why the Striatum Bears the Brunt
Huntingtin is made in every tissue, so you might expect the disease to affect the whole brain equally. Instead, the striatum, a deep brain region involved in movement control, decision-making, and habit formation, is hit earliest and hardest. About 95 percent of the neurons there are medium spiny neurons (MSNs), and they are the cells that die first.15Frontiers in Cellular Neuroscience. D1R- and D2R-Medium-Sized Spiny Neurons Diversity: Insights Into Striatal Vulnerability to Huntington’s Disease Mutation Why MSNs are so vulnerable remains one of the central puzzles of the field. Part of the answer appears to involve excitotoxicity: RNA analysis of an animal model identified that MSNs ramp up the production of certain glutamate receptors early in the disease process, making them hypersensitive to excitatory signals that eventually overwhelm and kill them.16PubMed Central. Single nuclei RNA-seq reveals a medium spiny neuron glutamate excitotoxicity signature prior to the onset of neuronal death in an ovine Huntington’s disease model
The brain’s immune cells compound the problem. Microglia, which normally patrol for threats, become chronically activated in Huntington’s disease. A PET imaging study found that the degree of microglial activation in patients’ brains correlated with how severe their symptoms were.17PubMed. Microglial activation correlates with severity in Huntington disease: a clinical and PET study Reactive astrocytes join the inflammatory cascade, and together these glial cells perpetuate a chronic inflammatory state that accelerates neuronal death.18PubMed Central. The Role of Microglia and Astrocytes in Huntington’s Disease While the initial immune response may be the brain attempting to protect itself, prolonged activation flips from neuroprotective to neurodestructive.19PubMed. Emerging roles of microglia and neuroinflammation in Huntington’s disease: From pathophysiology to clinical trials
Somatic Expansion and the DNA Time Bomb
The CAG repeat length you inherit sets the stage, but it is not the whole story. Inside the brain, the repeat keeps growing throughout life in a process called somatic expansion. A landmark 2024 study examining individual striatal neurons found that the inherited repeat of 40 to 45 CAGs had expanded to anywhere from 100 to over 500 CAGs within the very neurons that were dying. Neurons with up to about 150 repeats appeared largely unaffected. But those that crossed the 150 threshold began losing the molecular hallmarks of their identity, switched on cell-death genes, and were lost.20PubMed Central. Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s disease This reframes the disease as fundamentally a DNA process: for most of a neuron’s life, the repeat is unstable but harmless, and neurodegeneration is triggered only when the expansion crosses a critical length in any individual cell.
Somatic expansion is measurable even in blood, not just in the brain. Longitudinal tracking over several years detected significant increases in blood-based somatic expansion ratios in people carrying the HD mutation, and those increases predicted subsequent shrinkage of the caudate and putamen, the two striatal structures most affected in the disease.21Nature Medicine. Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis This means somatic expansion could serve as a measurable indicator of disease progression, potentially even before symptoms emerge.
Not everyone with the same inherited repeat length expands at the same rate, and researchers have identified specific genes that influence the pace. One of the best-studied is FAN1, a DNA repair enzyme. In cell models, knocking out FAN1 nearly doubled the speed of repeat expansion, while restoring it slowed the repeat’s growth significantly.22PubMed Central. FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat Genetic variants in FAN1 and related DNA-repair genes help explain why two people can inherit the same CAG repeat length yet develop symptoms years apart. These modifier genes are now a major focus of research because slowing somatic expansion could, in principle, delay disease onset even without touching the mutant protein itself.
Blood Biomarkers for Tracking the Disease
Huntington’s disease has long been trackable only through clinical exams and brain imaging, both of which pick up changes relatively late. Fluid biomarkers are changing that picture. Two proteins have emerged as leading candidates: mutant huntingtin (mHTT), measurable in cerebrospinal fluid, and neurofilament light chain (NfL), measurable in both spinal fluid and blood plasma. In a head-to-head comparison, NfL levels in plasma correlated more closely with clinical measures and brain imaging than mHTT did, and NfL in both plasma and cerebrospinal fluid could distinguish people who had crossed from the pre-symptom stage into active disease.23PubMed. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease
NfL also shows promise as a predictor of future decline. In a study of over 100 people carrying the HTT mutation but not yet showing symptoms, higher plasma NfL at baseline was associated with a roughly threefold greater risk of clinical onset over the following three years, an association that held even after adjusting for age, CAG length, and brain volume.24PubMed Central. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis Because NfL is a general marker of nerve-cell damage rather than something specific to huntingtin, it is not diagnostic on its own. But paired with genetic confirmation, a simple blood draw measuring NfL could one day help clinicians decide when to start treatment in someone who carries the mutation but feels fine.
Therapeutic Strategies Aimed at Lowering Huntingtin
Because the disease flows from a single gene, the most direct strategy is to reduce the amount of the toxic protein the gene produces. Several approaches are in various stages of development.
Antisense oligonucleotides (ASOs) are short synthetic strands of modified DNA that bind to the messenger RNA transcribed from the HTT gene and trigger its degradation, preventing the cell from making the protein. ASOs distribute broadly through the central nervous system and are taken up by neurons, glia, and the cells lining the brain’s ventricles.25PubMed Central. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic The first ASO to reach patients, tominersen (originally known as HTTRx), was designed to inhibit HTT messenger RNA and showed dose-dependent lowering of mutant huntingtin in cerebrospinal fluid in an early-phase trial.26PubMed. Targeting Huntingtin Expression in Patients with Huntington’s Disease However, the larger follow-up trial was stopped early because the drug did not slow decline and may have worsened outcomes in a subset of patients. The failure was a major setback, but it did not invalidate the concept. A key question is whether the drug lowered normal huntingtin too aggressively alongside the mutant form, or whether the dosing schedule was wrong. Several next-generation ASOs that selectively target the mutant allele are now being tested.
Delivering ASOs to the brain currently requires lumbar puncture, which limits convenience. Researchers are exploring delivery vehicles such as apolipoprotein A-I nanodisks, lipid-based particles that could carry ASOs across the blood-brain barrier after a simple intravenous injection.27PubMed. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease If successful, this would transform ASO therapy from an invasive hospital procedure into something closer to a routine infusion.
Small-molecule splicing modifiers represent yet another angle. These are pills that can be taken orally and reach the brain through the bloodstream. They work by tricking the cell’s RNA-processing machinery into inserting a premature stop signal into the HTT transcript, which flags it for destruction before the protein is ever made. Preclinical work has shown these compounds lower huntingtin consistently across the brain and peripheral organs.28PubMed Central. Small molecule splicing modifiers with systemic HTT-lowering activity Several are now in clinical trials.
Gene editing using tools like CRISPR/Cas9 sits further down the pipeline. In cell models derived from patients, the expanded CAG repeat has been corrected by cutting out the mutation and replacing it with normal DNA, restoring healthy huntingtin production.29PubMed Central. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease The main hurdles are delivery (getting the editing machinery into enough neurons in a living brain) and safety (making sure cuts happen only where intended). No CRISPR-based therapy for Huntington’s disease has reached clinical trials in humans yet, but work in animal models is advancing.
Juvenile-Onset Huntington’s Disease
When the CAG repeat is very long, typically 60 or more, symptoms can begin in childhood or adolescence. This juvenile-onset form accounts for roughly 5 percent of all cases and looks different from the adult version.30PubMed Central. Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review Instead of the involuntary writhing movements (chorea) that characterize adult-onset Huntington’s, children more often present with stiffness, slowed movement, seizures, and rapid cognitive decline. The brain pathology is also more severe, with broader and faster degeneration of striatal and cortical structures.
Because the very long repeats that cause juvenile onset almost always arise through paternal transmission, genetic counseling for families with an affected father includes discussing the possibility that an already-expanded repeat could grow further during sperm production.7PubMed Central. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease Prenatal and preimplantation genetic testing can identify an expanded repeat before or during pregnancy, giving families information to guide decisions.
The Huntingtin Gene Across Evolution
Huntingtin is ancient. The gene exists across vertebrates and has even been found in the sea squirt Ciona, a small marine invertebrate that diverged from the vertebrate lineage over 500 million years ago. The Ciona version of the protein is shorter and, critically, lacks the polyglutamine and polyproline stretches found near the front of the mammalian protein.31PubMed Central. Huntingtin gene evolution in Chordata and its peculiar features in the ascidian Ciona genus The overall gene structure, the way exons and introns are organized, is highly conserved between Ciona and vertebrates, pointing to an ancestral gene with at least 40 protein-coding segments.
The polyglutamine tract itself appears to be a more recent addition that grew as mammals diversified. In most species the repeat is short and stable. Humans sit at the upper end of the normal range, and some researchers have speculated that moderate glutamine-tract length may have been mildly beneficial for brain function, which would explain why evolution did not simply eliminate the repeat. The trade-off is that a longer baseline repeat is closer to the threshold for instability and disease, an evolutionary gamble that, for a small fraction of people, goes badly wrong.